ES8201949A1 - Un procedimiento para la preparacion de nuevos derivados cis750 mericos de 4-fenil-1,2,3,4-tetahidro-1-naftalenamina. - Google Patents

Un procedimiento para la preparacion de nuevos derivados cis750 mericos de 4-fenil-1,2,3,4-tetahidro-1-naftalenamina.

Info

Publication number
ES8201949A1
ES8201949A1 ES496443A ES496443A ES8201949A1 ES 8201949 A1 ES8201949 A1 ES 8201949A1 ES 496443 A ES496443 A ES 496443A ES 496443 A ES496443 A ES 496443A ES 8201949 A1 ES8201949 A1 ES 8201949A1
Authority
ES
Spain
Prior art keywords
tetrahydro
cis
naphthalenamine
phenyl
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES496443A
Other languages
English (en)
Other versions
ES496443A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22221931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8201949(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES8201949A1 publication Critical patent/ES8201949A1/es
Publication of ES496443A0 publication Critical patent/ES496443A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
    • C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE DERIVADOS CIS-ISOMERICOS DE 4-FENIL-1,2,3,4-TETRAHIDRO-1-NAFTALENAMINA DE FORMULA (I), ASI COMO DE SUS SALES DE ADICION DE ACIDO FISIOLOGICAMENTE COMPATIBLES, EN LA QUE R1 ES HIDROGENO O ALQUILO C1-3; R2 ES ALQUILO C1-3; Z ES RADICAL DE FORMULA (II), DONDE X E Y, JUNTO CON W, PUEDEN SER VARIOS TIPOS DE RADICALES. CONSISTE EN LA REACCION DE CONDENSACION DE UN COMPUESTO DE FORMULA (III), CON UNA AMINA DE FORMULA HNR1R2, N LAS QUEE R1, R2, W, X E Y TIENEN EL MISMO SIGNIFICADO QUE LA FORMULA (I), EN PRESENCIA DE UN CATALIZADOR ACIDO, TAL COMO TETRACLORURO DE TITANIO, SEGUIDA DE LA REDUCCION POR HIDROGENACION CATALITICA O CON UN HIDRURO METALICO COMPLEJO.
ES496443A 1979-11-01 1980-10-31 Un procedimiento para la preparacion de nuevos derivados cis750 mericos de 4-fenil-1,2,3,4-tetahidro-1-naftalenamina. Granted ES496443A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/090,240 US4536518A (en) 1979-11-01 1979-11-01 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

Publications (2)

Publication Number Publication Date
ES8201949A1 true ES8201949A1 (es) 1982-01-16
ES496443A0 ES496443A0 (es) 1982-01-16

Family

ID=22221931

Family Applications (2)

Application Number Title Priority Date Filing Date
ES496443A Granted ES496443A0 (es) 1979-11-01 1980-10-31 Un procedimiento para la preparacion de nuevos derivados cis750 mericos de 4-fenil-1,2,3,4-tetahidro-1-naftalenamina.
ES506892A Granted ES506892A0 (es) 1979-11-01 1981-11-05 Un procedimiento para la preparacion de nuevos derivados cis-isomericos de 4-fenil-1,2,3,4-tetrahidro-1-naftalenani- na.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES506892A Granted ES506892A0 (es) 1979-11-01 1981-11-05 Un procedimiento para la preparacion de nuevos derivados cis-isomericos de 4-fenil-1,2,3,4-tetrahidro-1-naftalenani- na.

Country Status (38)

Country Link
US (1) US4536518A (es)
EP (1) EP0030081B1 (es)
JP (1) JPS605584B2 (es)
KR (2) KR840002001B1 (es)
AT (1) ATE2668T1 (es)
AU (1) AU517357B2 (es)
BA (2) BA97150B1 (es)
BG (1) BG60333B2 (es)
CA (1) CA1130815A (es)
CS (4) CS238609B2 (es)
DD (2) DD203045A5 (es)
DE (2) DE3062225D1 (es)
DK (1) DK153390C (es)
EG (1) EG15527A (es)
ES (2) ES496443A0 (es)
FI (1) FI68806C (es)
GR (1) GR70781B (es)
HK (1) HK82284A (es)
HR (2) HRP930199B1 (es)
HU (1) HU182224B (es)
IE (1) IE50395B1 (es)
IL (1) IL61374A (es)
IN (2) IN159643B (es)
LU (1) LU88330I2 (es)
LV (2) LV5457A3 (es)
MX (1) MX5980E (es)
MY (1) MY8500326A (es)
NL (1) NL940018I1 (es)
NO (2) NO148996C (es)
NZ (1) NZ195407A (es)
PH (1) PH17319A (es)
PT (1) PT72004B (es)
SG (1) SG56584G (es)
SI (2) SI8012798A8 (es)
SU (2) SU1014467A3 (es)
UA (2) UA6301A1 (es)
YU (2) YU41951B (es)
ZA (1) ZA806726B (es)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4839104A (en) * 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4777288A (en) * 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
FR2623802B1 (fr) * 1987-11-26 1990-05-04 Lucien Laboratoires Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique
US4855500A (en) * 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
FR2632633B1 (fr) * 1988-06-08 1991-04-05 Delalande Sa Procede de preparation de 4-aryl-1-tetralones
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
DK0415612T3 (da) * 1989-08-30 1993-12-13 Pfizer Anvendelse af sertralin til behandling af afhængigheder af kemiske stoffer
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
FR2665443B1 (fr) * 1990-08-03 1992-11-06 Lucien Laboratoires Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
US5082970A (en) * 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5196607A (en) * 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5288916A (en) 1993-03-25 1994-02-22 Bend Research, Inc. Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
EP0724552B1 (en) * 1993-11-30 1997-10-29 Pfizer Inc. Process for preparing a chiral tetralone
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
WO1996041633A1 (en) * 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (en) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) * 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
NZ501251A (en) * 1997-07-01 2001-09-28 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
IN191358B (es) 1998-01-16 2003-11-29 Pfizer Prod Inc
WO1999046233A1 (fr) * 1998-03-09 1999-09-16 Sumika Fine Chemicals Co., Ltd. Derives de l'alcool benzylique
WO1999047486A1 (en) 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
FR2777000B1 (fr) 1998-04-01 2002-09-27 Catalys Procede de preparation de la sertraline racemique
EP0957099B1 (en) * 1998-04-15 2002-11-20 Pfizer Products Inc. Heterocyclic carboxamides
US6054614A (en) * 1998-04-23 2000-04-25 Ciba Specialty Chemicals Corporation Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
HU226424B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing enantiomer mixture for preparation of sertraline
HU226423B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing a 1(2h)-naphtalene-1-ylidene derivative
IN182588B (es) * 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
CN1184962C (zh) * 1998-10-13 2005-01-19 辉瑞产品公司 口服舍曲林浓缩物
IL132500A0 (en) 1998-10-29 2001-03-19 Pfizer Prod Inc Stereoselective microbial reduction of a racemic tetralone
AU1031500A (en) * 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ATE315544T1 (de) * 1998-11-27 2006-02-15 Teva Pharma Sertralin hydrochlorid form v
EP1637515A1 (en) * 1998-11-27 2006-03-22 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
DE60021859T2 (de) * 1999-03-01 2006-06-01 Pfizer Inc. 1, 2, 3, 4-tetrahydro-1-naphthalenamin verbindungen zur therapeutsichen verwendung
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
YU32700A (sh) 1999-06-09 2002-03-18 Pfizer Products Inc. Postupak za dobijanje sertralina iz hiralnog tetralona
ATE264831T1 (de) * 1999-07-29 2004-05-15 Ciba Sc Holding Ag Verfahren zur cis-selektiven katalytischen hydrierung von cyclohexylidenaminen
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
IN185109B (es) * 1999-09-01 2000-11-18 Torrent Pharmaceuticals Ltd
DK174219B1 (da) * 1999-10-27 2002-09-30 Gea Farmaceutisk Fabrik As Forbedret syntese af racemisk sertralin
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
HUP0203384A3 (en) * 1999-11-16 2006-02-28 Ciba Sc Holding Ag Process for the preparation of ketimines
PT1230212E (pt) 1999-11-16 2005-08-31 Ciba Sc Holding Ag Metodo de embalar elementos de construcao de brinquedo
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
ES2281374T3 (es) * 1999-12-21 2007-10-01 Teva Pharmaceutical Industries Ltd. Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion.
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
IN187170B (es) 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
AU2001243634B2 (en) 2000-03-14 2006-05-25 Teva Pharmaceutical Industries Ltd. Novel process for preparing (+)-cis-sertraline
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
IN192343B (es) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
EP1184372B1 (en) * 2000-08-31 2006-04-26 Pfizer Limited Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs)
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
EP1397343A1 (en) * 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
US6723878B2 (en) 2001-06-15 2004-04-20 Orion Corporation Fermion Method for preparing sertraline
EP1401800A1 (en) * 2001-06-15 2004-03-31 Orion Corporation Fermion A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
CN101921267A (zh) * 2001-10-12 2010-12-22 阿泽范药品公司 β-内酰胺后叶加压素V1a拮抗剂
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
EP1499581A1 (en) * 2002-04-29 2005-01-26 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
WO2004011413A1 (en) * 2002-07-29 2004-02-05 Cipla Limited Sertraline
RU2310647C2 (ru) * 2002-11-07 2007-11-20 Торрент Фармасьютикалз Лтд Способ получения полиморфной формы гидрохлорида сертралина
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2004087732A2 (en) * 2003-03-11 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthylamine
TW200503991A (en) * 2003-04-14 2005-02-01 Teva Pharma Hydrogenation of imine intermediates of sertraline with catalysts
US7186863B2 (en) * 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
WO2005012224A1 (en) * 2003-07-15 2005-02-10 Recordati Industria Chimica E Farmaceutica S.P.A. Sertraline hydrochloride form ii and methods for the preparation thereof
WO2005012225A1 (en) * 2003-07-15 2005-02-10 Recordati Industria Chimica E Farmaceutica S.P.A. Methods for preparing sertraline hydrochloride polymorphs
HU227495B1 (en) * 2003-07-21 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing of imine intermediate
EP1660432A2 (en) * 2003-09-05 2006-05-31 Teva Pharmaceutical Industries Limited A recycling process for preparing sertraline
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
CN103788089A (zh) * 2003-09-17 2014-05-14 詹森药业有限公司 作为血清素受体调节剂的稠合杂环化合物
RU2376279C2 (ru) * 2003-11-04 2009-12-20 Сипла Лимитед Способ получения полиморфов ингибитора повторного захвата серотонина (варианты)
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
WO2005051488A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
CA2565159A1 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
TW200640836A (en) * 2005-02-23 2006-12-01 Teva Pharma Processes for preparing sertraline
WO2006102308A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
JP2006265169A (ja) * 2005-03-24 2006-10-05 Tokuyama Corp アルキリデンコハク酸化合物の製造方法
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2006116165A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
WO2006116218A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2006129324A2 (en) * 2005-06-03 2006-12-07 Hetero Drugs Limited A highly stereoselective synthesis of sertraline
WO2007008317A2 (en) * 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Process for preparation of sertraline hydrochloride form i
US7884136B2 (en) * 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
CA2614289A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
AU2006270039B2 (en) 2005-07-19 2013-07-04 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
AU2006335174B2 (en) * 2006-01-06 2012-09-06 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US20070213562A1 (en) * 2006-01-23 2007-09-13 Ami Zoran Recycling process for preparing sertraline
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
WO2007119247A2 (en) * 2006-04-17 2007-10-25 Unichem Laboratories Limited Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride)
TR200808115T1 (tr) * 2006-04-28 2009-03-23 Sandoz Ag 4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
WO2007146796A2 (en) * 2006-06-13 2007-12-21 Ramot At Tel-Aviv University Ltd. Antiproliferative compounds, compositions and methods of use
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9260413B2 (en) * 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2011163231A2 (en) 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
PL2587919T3 (pl) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Sposoby leczenia zespołu stresu pourazowego
AU2012227936A1 (en) 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101340270B1 (ko) * 2011-11-10 2013-12-10 보령제약 주식회사 (+)-시스-서트랄린의 선택적인 제조방법
EA026941B1 (ru) * 2012-10-18 2017-06-30 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ АКТИВНОСТИ РЕЦЕПТОРА mGluR5
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
US10266481B2 (en) 2014-06-20 2019-04-23 Council Of Scientific & Industrial Research Organocatalytic asymmetric synthesis of antidepressants
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016023825A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016023832A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
JP7405341B2 (ja) 2015-09-21 2023-12-26 エス．シー． ジョンソン アンド サン、インコーポレイテッド 混合及び散布のシステム
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral
WO2020043716A1 (en) 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Pharmacological targeting of de novo serine/glycine synthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887509A (en) * 1956-11-05 1959-05-19 Lilly Co Eli Hydroxybenzoyl benzoate salt of beta-(o-chlorophenyl)-beta-hydroxyethyl isopropylamine
US3704323A (en) * 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
US4029731A (en) * 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds
US4045488A (en) * 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds

Also Published As

Publication number Publication date
LU88330I2 (fr) 1994-05-04
JPS605584B2 (ja) 1985-02-12
PH17319A (en) 1984-07-20
CS354291A3 (en) 1992-12-16
KR830004202A (ko) 1983-07-06
EG15527A (en) 1987-04-30
SU1014467A3 (ru) 1983-04-23
BG60333B2 (bg) 1994-11-30
BA97150B1 (bs) 1998-12-28
FI803398L (fi) 1981-05-02
CS238609B2 (en) 1985-12-16
ATE2668T1 (de) 1986-03-15
HRP931527B1 (en) 1996-04-30
ES8207123A1 (es) 1982-09-01
SU1034602A3 (ru) 1983-08-07
CS238617B2 (en) 1985-12-16
CA1130815A (en) 1982-08-31
NO148996C (no) 1984-01-25
BA97149B1 (bs) 1998-12-28
UA6301A1 (uk) 1994-12-29
KR840002001B1 (ko) 1984-10-27
NL940018I1 (nl) 1994-10-17
NO1996011I1 (no) 1996-09-24
HK82284A (en) 1984-11-09
YU279880A (en) 1983-09-30
IL61374A0 (en) 1980-12-31
DK153390B (da) 1988-07-11
EP0030081A1 (en) 1981-06-10
NO148996B (no) 1983-10-17
DE19775012I2 (de) 2001-02-08
IN159643B (es) 1987-05-30
LV5457A3 (lv) 1994-03-10
JPS5686137A (en) 1981-07-13
IN159644B (es) 1987-05-30
NO803258L (no) 1981-05-04
CS238618B2 (en) 1985-12-16
SI8310672A8 (en) 1996-04-30
DD203045A5 (de) 1983-10-12
AU517357B2 (en) 1981-07-23
LV5456A3 (lv) 1994-03-10
EP0030081B1 (en) 1983-03-02
KR840002000B1 (ko) 1984-10-27
AU6389780A (en) 1981-05-07
YU67283A (en) 1983-10-31
ZA806726B (en) 1981-10-28
FI68806C (fi) 1985-11-11
IL61374A (en) 1983-10-31
IE802259L (en) 1981-05-01
MX5980E (es) 1984-09-12
HU182224B (en) 1983-12-28
HRP930199B1 (en) 1996-02-29
GR70781B (es) 1983-03-23
US4536518A (en) 1985-08-20
UA6311A1 (uk) 1994-12-29
NZ195407A (en) 1984-05-31
PT72004A (en) 1980-11-01
DE3062225D1 (en) 1983-04-07
ES506892A0 (es) 1982-09-01
FI68806B (fi) 1985-07-31
IE50395B1 (en) 1986-04-16
DK153390C (da) 1988-12-05
SI8012798A8 (sl) 1994-12-31
YU42846B (en) 1988-12-31
DK395280A (da) 1981-05-02
ES496443A0 (es) 1982-01-16
PT72004B (en) 1981-08-31
MY8500326A (en) 1985-12-31
SG56584G (en) 1985-03-08
YU41951B (en) 1988-02-29
DD155615A5 (de) 1982-06-23

Similar Documents

Publication Publication Date Title
ES8207123A1 (es) Un procedimiento para la preparacion de nuevos derivados cis-isomericos de 4-fenil-1,2,3,4-tetrahidro-1-naftalenani- na.
ES8201948A1 (es) Un procedimiento para la preparacion de nuevos derivados transisomericos de 4-fenil-1,2,3,4- tetrahidro-1-naftalenamina.
MY136249A (en) Phenylethanolamine compounds as anti-obesity agents
SE8206230D0 (sv) Novel cyclic imines, their preparation and pharmaceutical compositions containing the same
GB878284A (en) 1-o-tolyloxyethyl-4-phenyl-piperidine

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20020117